Mick Bhatia’s lab has found that the antipsychotic drug, Thioridazine, has activity against cancer stem cells.
The work, published in Cell (read paper here), indicates that Thioridazine works not by killing cancer stem cells, but rather by encouraging the stem cells to differentiate.
Bhatia’s group used a novel screening approach (see graphical abstract from the paper above) to find molecules that specifically differentiate cancer stem cells. Interestingly they found Thioridazine, which intriguingly targets the dopamine receptor expressed on certain cancer stem cells. Bhatia can be seen in the interview below talking about the finding.
You might think then that Thioridazine would be safe because it only targets cells expressing dopamine receptor, however the drug reportedly has significant safety concerns due to causing fatal heart arrhythmias and regulators have largely phased it out in both Canada and the U.S..
Even so, it may be safe for cancer treatments since it could be used for a much shorter period of time, speculated Bhatia. However it is still early days in this story so there is much to learn about this new route to attacking cancer. Still, a very exciting and important development.
Thanks to https://www.ipscell.com/2012/05/psyching-out-cancer-stem-cells-using-old-antipsychotic-drug-as-a-new-weapon-against-cancer/ for the information.
This comment has been removed by the author.
ReplyDeleteThioridazine has the potential to serve as an adjuvant with anticancer agents, rendering the a priori MDR cancer cells susceptible to the anticancer agent. Know more uses here http://www.internationaldrugmart.com/thioridazine.html
ReplyDeleteNice post! This is a very nice blog that I will definitively come back to more times this year! Thanks for informative post. multiple drug interactions
ReplyDeleteYou make so many great points here that I read your article a couple of times. Your views are in accordance with my own for the most part. This is great content for your readers. Drug interactions
ReplyDelete